# Wenhui Li

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 85 papers | 13,835 citations | 44 h-index | 87 g-index |
| 87 ext. papers | 16,351 ext. citations | 9.6 avg, IF | 5.92 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 85 | DExD/H-box helicase 9 intrinsically controls CD8 T cell-mediated antiviral response through noncanonical mechanisms.. *Science Advances*, **2022**, 8, eabk2691 | 14.3 | 1 |
| 84 | Phenotypic and functional characterizations of CD8 T cell populations in malignant pleural effusion.. *Experimental Cell Research*, **2022**, 113212 | 4.2 | 0 |
| 83 | Enforced PGC-1α expression promotes CD8 T cell fitness, memory formation and antitumor immunity. *Cellular and Molecular Immunology*, **2021**, 18, 1761-1771 | 15.4 | 24 |
| 82 | Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue. *Journal of Medicinal Chemistry*, **2021**, 64, 543-565 | 8.3 | 3 |
| 81 | Design of Dimeric Bile Acid Derivatives as Potent and Selective Human NTCP Inhibitors. *Journal of Medicinal Chemistry*, **2021**, 64, 5973-6007 | 8.3 | 2 |
| 80 | Animal Models for Hepatitis B: Does the Supply Meet the Demand?. *Gastroenterology*, **2021**, 160, 1437-1442 | 13.3 | 1 |
| 79 | An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines. *MBio*, **2021**, 12, | 7.8 | 6 |
| 78 | Transcriptionally inactive hepatitis B virus episome DNA preferentially resides in the vicinity of chromosome 19 in 3D host genome upon infection. *Cell Reports*, **2021**, 35, 109288 | 10.6 | 3 |
| 77 | NTCP Deficiency Causes Gallbladder Abnormalities in Mice and Human Beings. *Cellular and Molecular Gastroenterology and Hepatology*, **2021**, 11, 831-839 | 7.9 | 4 |
| 76 | Entry of hepatitis B virus: going beyond NTCP to the nucleus. *Current Opinion in Virology*, **2021**, 50, 97-102 | 7.5 | 0 |
| 75 | Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. *Nature Nanotechnology*, **2020**, 15, 406-416 | 28.7 | 71 |
| 74 | Novel Abs targeting the N-terminus of fibroblast growth factor 19 inhibit hepatocellular carcinoma growth without bile-acid-related side-effects. *Cancer Science*, **2020**, 111, 1750-1760 | 6.9 | 4 |
| 73 | An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines **2020**, | | 4 |
| 72 | Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test. *Biosafety and Health*, **2020**, 2, 226-231 | 4.7 | 33 |
| 71 | Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. *EBioMedicine*, **2020**, 58, 102890 | 8.8 | 15 |
| 70 | SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. *Nature Communications*, **2020**, 11, 6013 | 17.4 | 450 |
| 69 | Mitochondrial Damage and the Road to Exhaustion. *Cell Metabolism*, **2020**, 32, 905-907 | 24.6 | 2 |

| | | | |
|---|---|---|---|
| 68 | Animal models for the study of human hepatitis B and D virus infection: New insights and progress. *Antiviral Research*, **2020**, 182, 104898 | 10.8 | 5 |
| 67 | Increased sulfation of bile acids in mice and human subjects with sodium taurocholate cotransporting polypeptide deficiency. *Journal of Biological Chemistry*, **2019**, 294, 11853-11862 | 5.4 | 17 |
| 66 | A global scientific strategy to cure hepatitis B. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 545-558 | 18.8 | 187 |
| 65 | Severe fever with thrombocytopenia syndrome phlebovirus non-structural protein activates TPL2 signalling pathway for viral immunopathogenesis. *Nature Microbiology*, **2019**, 4, 429-437 | 26.6 | 29 |
| 64 | Silencing Retinoid X Receptor Alpha Expression Enhances Early-Stage Hepatitis B Virus Infection In Cell Cultures. *Journal of Virology*, **2018**, 92, | 6.6 | 25 |
| 63 | Receptor Usage of a Novel Bat Lineage C Betacoronavirus Reveals Evolution of Middle East Respiratory Syndrome-Related Coronavirus Spike Proteins for Human Dipeptidyl Peptidase 4 Binding. *Journal of Infectious Diseases*, **2018**, 218, 197-207 | 7 | 59 |
| 62 | The p.Ser267Phe variant of sodium taurocholate cotransporting polypeptide (NTCP) supports HBV infection with a low efficiency. *Virology*, **2018**, 522, 168-176 | 3.6 | 9 |
| 61 | The immune response of rhesus macaques to novel vaccines comprising hepatitis B virus S, PreS1, and Core antigens. *Vaccine*, **2018**, 36, 3740-3746 | 4.1 | 7 |
| 60 | Woodchuck sodium taurocholate cotransporting polypeptide supports low-level hepatitis B and D virus entry. *Virology*, **2017**, 505, 1-11 | 3.6 | 12 |
| 59 | Recombinant vaccinia vector-based vaccine (Tiantan) boosting a novel HBV subunit vaccine induced more robust and lasting immunity in rhesus macaques. *Vaccine*, **2017**, 35, 3347-3353 | 4.1 | 5 |
| 58 | Sleep Duration and Cardiometabolic Risk Among Chinese School-aged Children: Do Adipokines Play a Mediating Role?. *Sleep*, **2017**, 40, | 1.1 | 22 |
| 57 | The History and Challenges of Blood Donor Screening in China. *Transfusion Medicine Reviews*, **2017**, 31, 89-93 | 7.4 | 15 |
| 56 | NTCP-Reconstituted In Vitro HBV Infection System. *Methods in Molecular Biology*, **2017**, 1540, 1-14 | 1.4 | 36 |
| 55 | A potent human neutralizing antibody Fc-dependently reduces established HBV infections. *ELife*, **2017**, 6, | 8.9 | 50 |
| 54 | HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. *PLoS Pathogens*, **2017**, 13, e1006658 | 7.6 | 71 |
| 53 | Modification of Three Amino Acids in Sodium Taurocholate Cotransporting Polypeptide Renders Mice Susceptible to Infection with Hepatitis D Virus In Vivo. *Journal of Virology*, **2016**, 90, 8866-74 | 6.6 | 26 |
| 52 | A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3. *Journal of Virological Methods*, **2016**, 232, 1-7 | 2.6 | 5 |
| 51 | DNA Polymerase Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus. *PLoS Pathogens*, **2016**, 12, e1005893 | 7.6 | 112 |

| | | | |
|---|---|---|---|
| 50 | Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. *Journal of Hepatology*, **2016**, 64, S32-S40 | 13.4 | 76 |
| 49 | Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide. *PLoS Pathogens*, **2015**, 11, e1004840 | 7.6 | 78 |
| 48 | NTCP opens the door for hepatitis B virus infection. *Antiviral Research*, **2015**, 121, 24-30 | 10.8 | 55 |
| 47 | Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus. *Digestive Diseases*, **2015**, 33, 388-96 | 3.2 | 11 |
| 46 | Human Coronavirus HKU1 Spike Protein Uses O-Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme. *Journal of Virology*, **2015**, 89, 7202-13 | 6.6 | 166 |
| 45 | The hepatitis B virus receptor. *Annual Review of Cell and Developmental Biology*, **2015**, 31, 125-47 | 12.6 | 44 |
| 44 | Role of high-risk variants in the development of impaired glucose metabolism was modified by birth weight in Han Chinese. *Diabetes/Metabolism Research and Reviews*, **2015**, 31, 790-5 | 7.5 | 3 |
| 43 | microRNA expression in hepatitis B virus infected primary treeshrew hepatocytes and the independence of intracellular miR-122 level for de novo HBV infection in culture. *Virology*, **2014**, 448, 247-54 | 3.6 | 14 |
| 42 | Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. *Journal of Virology*, **2014**, 88, 3273-84 | 6.6 | 166 |
| 41 | Angiotensin-Converting Enzyme 2, the Cellular Receptor for Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 **2014**, 147-156 | | |
| 40 | miR-375 and miR-30d in the effect of chromium-containing Chinese medicine moderating glucose metabolism. *Journal of Diabetes Research*, **2014**, 2014, 862473 | 3.9 | 16 |
| 39 | NTCP and beyond: opening the door to unveil hepatitis B virus entry. *International Journal of Molecular Sciences*, **2014**, 15, 2892-905 | 6.3 | 100 |
| 38 | Nonmuscle myosin heavy chain IIA is a critical factor contributing to the efficiency of early infection of severe fever with thrombocytopenia syndrome virus. *Journal of Virology*, **2014**, 88, 237-48 | 6.6 | 59 |
| 37 | Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. *Journal of Virology*, **2013**, 87, 7977-91 | 6.6 | 127 |
| 36 | Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. *PLoS Pathogens*, **2013**, 9, e1003613 | 7.6 | 112 |
| 35 | TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. *PLoS Pathogens*, **2013**, 9, e1003232 | 7.6 | 223 |
| 34 | Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes. *Journal of Virology*, **2013**, 87, 7176-84 | 6.6 | 53 |
| 33 | Site-specific engineering of chemical functionalities on the surface of live hepatitis D virus. *Angewandte Chemie - International Edition*, **2013**, 52, 13970-4 | 16.4 | 47 |

| | | | |
|---|---|---|---|
| 32 | Site-Specific Engineering of Chemical Functionalities on the Surface of Live Hepatitis D Virus. *Angewandte Chemie*, **2013**, 125, 14220-14224 | 3.6 | 9 |
| 31 | Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71. *PLoS ONE*, **2013**, 8, e64116 | 3.7 | 21 |
| 30 | Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. *Journal of Biological Chemistry*, **2012**, 287, 6406-20 | 5.4 | 99 |
| 29 | Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. *ELife*, **2012**, 1, e00049 | 8.9 | 1216 |
| 28 | Structural basis for activation and inhibition of the secreted chlamydia protease CPAF. *Cell Host and Microbe*, **2008**, 4, 529-42 | 23.4 | 62 |
| 27 | Influenza A virus neuraminidase limits viral superinfection. *Journal of Virology*, **2008**, 82, 4834-43 | 6.6 | 104 |
| 26 | Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. *Nature* , **2007**, 446, 92-6 | 50.4 | 314 |
| 25 | The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. *Virology*, **2007**, 367, 367-74 | 3.6 | 119 |
| 24 | Severe Acute Respiratory Syndrome Coronavirus Entry as a Target of Antiviral Therapies. *Antiviral Therapy*, **2007**, 12, 639-650 | 1.6 | 12 |
| 23 | Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. *Journal of Medical Virology*, **2006**, 78, 1-8 | 19.7 | 152 |
| 22 | Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain. *Journal of Virology*, **2006**, 80, 6794-800 | 6.6 | 96 |
| 21 | Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. *Journal of Biological Chemistry*, **2006**, 281, 15951-8 | 5.4 | 104 |
| 20 | Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. *Journal of Virology*, **2006**, 80, 4211-9 | 6.6 | 206 |
| 19 | SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. *Journal of Biological Chemistry*, **2006**, 281, 3198-203 | 5.4 | 261 |
| 18 | Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. *Journal of Immunology*, **2006**, 176, 6085-92 | 5.3 | 93 |
| 17 | The SARS Coronavirus receptor ACE 2 A potential target for antiviral therapy **2006**, 397-418 | | 11 |
| 16 | Insights from the association of SARS-CoV S-protein with its receptor, ACE2. *Advances in Experimental Medicine and Biology*, **2006**, 581, 209-18 | 3.6 | 16 |
| 15 | Interactions between SARS coronavirus and its receptor. *Advances in Experimental Medicine and Biology*, **2006**, 581, 229-34 | 3.6 | 11 |

| | | | |
|---|---|---|---|
| 14 | SARS-CoV, but not HCoV-NL63, utilizes cathepsins to infect cells: viral entry. *Advances in Experimental Medicine and Biology*, **2006**, 581, 335-8 | 3.6 | 21 |
| 13 | Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). *Molecular Microbiology*, **2005**, 55, 1413-22 | 4.1 | 118 |
| 12 | Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. *EMBO Journal*, **2005**, 24, 1634-43 | 13 | 710 |
| 11 | Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. *Science*, **2005**, 309, 1864-8 | 33.3 | 1383 |
| 10 | Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. *Journal of Virology*, **2005**, 79, 5900-6 | 6.6 | 129 |
| 9 | Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. *Journal of Virology*, **2004**, 78, 11429-33 | 6.6 | 139 |
| 8 | A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. *Journal of Biological Chemistry*, **2004**, 279, 3197-201 | 5.4 | 528 |
| 7 | Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. *Journal of Virology*, **2004**, 78, 10628-35 | 6.6 | 197 |
| 6 | Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. *Biochemical and Biophysical Research Communications*, **2004**, 324, 773-81 | 3.4 | 316 |
| 5 | Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 2536-41 | 11.5 | 481 |
| 4 | Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature*, **2003**, 426, 450-4 | 50.4 | 3969 |
| 3 | Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. *Cell*, **2003**, 114, 161-70 | 56.2 | 166 |
| 2 | Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region. *Journal of Biological Chemistry*, **2002**, 277, 40397-402 | 5.4 | 48 |
| 1 | The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement | | 59 |